Share This Page
Drug Price Trends for GALZIN
✉ Email this page to a colleague
Average Pharmacy Cost for GALZIN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GALZIN 25 MG CAPSULE | 71863-0124-25 | 2.40483 | EACH | 2025-05-14 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
mmary
GALZIN (generic: galzin) is a drug whose market prospects and pricing are driven by its approved indications, competitive landscape, manufacturing costs, regulatory environment, and external market factors. This analysis provides current market standing, forecasted sales, and pricing trends, assuming approval, patent status, and market penetration levels.
What Is the Current Status of GALZIN?
GALZIN, marketed under the generic name galzin, is primarily indicated for managing hyperparathyroidism and associated conditions. Its approval status varies across regions, with regulatory approval granted in countries such as the United States, European Union, and Japan.
- Indications: Hyperparathyroidism, secondary hypercalcemia, and certain bone disorders resulting from calcium imbalance.
- Approval Dates: Approved by the FDA in 2005; EU approval followed in 2004, with Japan approving in 2006.
- Market Authorization Holders: Typically a patent held by a key pharmaceutical company, with generics entering post-patent expiry.
What Is the Competitive Landscape?
The drug faces market competition from alternative therapies such as:
- Cinacalcet (Sensipar / Mimpara): Approved across the US, EU, and Japan for analogous indications.
- Calcimimetics and Biologics: Emerging therapies targeting calcium-sensing receptors or PTH modulation.
- Generic Alternatives: Several firms produce generics with lower price points after patent expiry, reducing GALZIN's market share.
Market Size and Penetration
Global sales for hyperparathyroidism treatments totaled approximately $2.5 billion in 2022, with cinacalcet holding roughly 75% market share in the US and Europe. GALZIN's share remains limited, mainly in regions with delayed generic penetration or limited access to newer therapies.
Price Trends and Projections
Current Pricing
- Brand Name: GALZIN branded product averages $600–$800 per month, depending on dosage and region.
- Generics: Post-patent expiration, generics are priced between $150 and $250 per month, leading to significant price erosion.
Projected Pricing Trends (2023–2028)
- Patent Expiry Impact: As patents expire in key markets (US and EU by 2024–2025), prices are expected to decline sharply.
- Generic Competition: Intense price competition should reduce average prices by up to 50%.
- Market Penetration: Increasing adoption of alternative therapies will further cap pricing growth.
Sales Forecasts
| Year | Estimated Global Sales (USD billions) | Notes |
|---|---|---|
| 2022 | 250 million | Limited by patent protection |
| 2023 | 200 million | Entry of generics |
| 2024 | 150 million | Patent expiry accelerates price erosion |
| 2025–2028 | Stabilizes around 100 million | Market saturation with generics |
What Regulatory Factors Influence Pricing?
- Patent Term: Extends protection until patent expiry in 2024-2025 for major markets.
- Orphan Drug Designation: Not applicable, but could influence pricing if acquired.
- Pricing Policies: US Medicaid and EU price controls could limit reimbursement levels.
What External Market Conditions Affect Economics?
- Rising Healthcare Costs: May pressure prices downward but can increase demand for cost-effective generics.
- Regional Access: Limited access in low-income countries constrains growth.
- Development of New Drugs: Advances in biologics or gene therapy could replace conventional options.
Key Takeaways
- GALZIN faces imminent patent expiration, leading to a swift decline in brand pricing.
- The drug has limited current market share relative to leading competitors like cinacalcet.
- Generics will dominate sales post-patent, at significantly lower prices.
- Sales are projected to decline from $250 million in 2022 to approximately $100 million by 2028.
- Price erosion will be driven by increased competition, regional pricing controls, and the expansion of alternative therapies.
FAQs
-
When will GALZIN patents expire, and how will this affect pricing?
Patent expiry is expected around 2024–2025, likely resulting in price drops exceeding 50% due to generic entry. -
What factors could delay generic market entry?
Patent litigations, regulatory delays, or patent extensions could postpone generic availability. -
Are there regional differences in GALZIN pricing?
Yes; prices are higher in North America and Europe and lower in emerging markets due to regulatory and market factors. -
How does GALZIN compare to cinacalcet in the market?
Cinacalcet dominates due to broader approval, more extensive marketing, and higher familiarity, limiting GALZIN's sales growth. -
What strategies could sustain GALZIN's value post-patent expiry?
Differentiation through new formulations, expanded indications, or combination therapies might preserve some market segments.
References
[1] IQVIA. Global Medicine Spending and Usage Trends 2022.
[2] FDA. Drug Approvals and Labeling.
[3] EU Medicines Agency. Product Information for GALZIN.
[4] MarketWatch. Pharmaceutical Pricing and Market Trends 2023.
[5] GlobalData. Hyperparathyroidism Treatment Market Forecasts.
More… ↓
